Skip to Main Content

Al Sandrock, the top scientist at Biogen who exited last year in a dispute over its controversial Alzheimer’s treatment, has landed a new job as the CEO of Voyager Therapeutics, the company said Tuesday.

Voyager’s appointment of Sandrock as its new CEO is the latest in a series of moves aimed at refocusing the company on a new gene therapy delivery technology, following setbacks with its earlier pipeline.


For Sandrock, accepting the Voyager CEO post is a reset following a long and distinguished career at Biogen that ended in crisis and his ouster. His departure from Biogen last November was characterized by the company as a retirement. But as STAT previously reported, Biogen CEO Michel Vounatsos forced Sandrock out, faulting him for the controversial approval and disastrous rollout of the Alzheimer’s drug Aduhelm.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.